Biopolym. Cell. 2005; 21(3):270-274.
Molecular and Cell Biotechnologies
Development of model DNA-vaccine
- Institute of Molecular Biology and Genetics, NAS of Ukraine
150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680
Abstract
The development of DNA-vaccines is one of the most perspective directions in modern vaccionology. However, despite rapid progress in their application, a broad range of questions concerning the basic mechanisms of induction of immune response to DNA-vaccination remains unanswered. A model DNA-vaccine, containing the gene of Escherichia coli β-galactosidase as the gene of model antigen, has been developed. The data obtained suggest that the created recombinant plasmid pBG-TR/02 is able to induce the humoral immune response to E. coli β-galactosidase in mice depending on the place of administration and, therefore, it can be used as the model DNA-vaccine for future research.
Keywords: DNA-vaccine, model antigen, immunization, humoral immune response
Full text: (PDF, in Ukrainian)
References
[1]
Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465-8.
[2]
Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259(5102):1745-9.
[3]
Huygen K. On the use of DNA vaccines for the prophylaxis of mycobacterial diseases. Infect Immun. 2003;71(4):1613-21.
[4]
Kordium VA, Pokholenko IaO, DNA-vaccines the expansion of opportunities. Journal of Pharmacology and Pharmacy. 2004; 10:2-9.
[5]
Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel ML. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci U S A. 1996;93(22):12496-501.
[6]
Calarota SA, Leandersson AC, Bratt G, Hinkula J, Klinman DM, Weinhold KJ, Sandström E, Wahren B. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J Immunol. 1999;163(4):2330-8.
[7]
Lowrie DB, Tascon RE, Bonato VL, Lima VM, Faccioli LH, Stavropoulos E, Colston MJ, Hewinson RG, Moelling K, Silva CL. Therapy of tuberculosis in mice by DNA vaccination. Nature. 1999;400(6741):269-71.
[8]
Wildbaum G, Youssef S, Karin N. A targeted DNA vaccine augments the natural immune response to self TNF-alpha and suppresses ongoing adjuvant arthritis. J Immunol. 2000;165(10):5860-6.
[9]
Quaglino E, Rolla S, Iezzi M, Spadaro M, Musiani P, De Giovanni C, Lollini PL, Lanzardo S, Forni G, Sanges R, Crispi S, De Luca P, Calogero R, Cavallo F. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J Clin Invest. 2004;113(5):709-17.
[10]
Weber LW, Bowne WB, Wolchok JD, Srinivasan R, Qin J, Moroi Y, Clynes R, Song P, Lewis JJ, Houghton AN. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest. 1998;102(6):1258-64.
[11]
Sambrook J., Fritsch E. E., Maniatis T. Molecular cloning. New York: Cold Spring Harbor Lab. press, 1989. 625 p.
[12]
Catalogue Russian cell culture collection (RCCC). St. Petersburg; Omsk, 1999. 204 p.
[13]
Herrington CS. Diagnostic Molecular Pathology: A Practical Approach : Cell and Tissue Genotyping. Ed. J. O'd Mcgee. Irl Pr; Spi edition 1992. 244 p.
[14]
Fisher RA. The statistical methods for researchers. M.: Gosstatizdat, 1958. 268 p.
[15]
Boshart M, Weber F, Jahn G, Dorsch-Häsler K, Fleckenstein B, Schaffner W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell. 1985;41(2):521-30.
[16]
Foecking MK, Hofstetter H. Powerful and versatile enhancer-promoter unit for mammalian expression vectors. Gene. 1986;45(1):101-5.
[17]
Xin KQ, Ooki T, Jounai N, Mizukami H, Hamajima K, Kojima Y, Ohba K, Toda Y, Hirai S, Klinman DM, Ozawa K, Okuda K. A DNA vaccine containing inverted terminal repeats from adeno-associated virus increases immunity to HIV. J Gene Med. 2003;5(5):438-45.
[18]
Chikhlikar P, Barros de Arruda L, Agrawal S, Byrne B, Guggino W, August JT, Marques ET Jr. Inverted terminal repeat sequences of adeno-associated virus enhance the antibody and CD8(+) responses to a HIV-1 p55Gag/LAMP DNA vaccine chimera. Virology. 2004;323(2):220-32.
[19]
Yokoyama M, Hassett DE, Zhang J, Whitton JL. DNA immunization can stimulate florid local inflammation, and the antiviral immunity induced varies depending on injection site. Vaccine. 1997;15(5):553-60.